M72/AS01E-4 Tuberculosis Vaccine: Promising Advances for HIV-Positive Populations in High-Burden Settings

Highlights

• Phase 2 trial of M72/AS01E-4 demonstrates robust immunogenicity and acceptable safety in virally suppressed, ART-treated people living with HIV (PLWH).
• Significant and durable antibody and CD4 T-cell responses to M72/AS01E-4 were observed up to one year after vaccination.
• Reactogenicity was higher in the vaccine group but no life-threatening or vaccine-related serious adverse events were reported.
• The data support further clinical development of M72/AS01E-4 as a candidate TB vaccine for the HIV-positive population.

Study Background and Disease Burden